426 related articles for article (PubMed ID: 28128058)
1. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Schreml J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a) Management: Pharmacological and Apheretic Treatment.
Hanssen R; Gouni-Berthold I
Curr Med Chem; 2017; 24(10):957-968. PubMed ID: 28078998
[TBL] [Abstract][Full Text] [Related]
3. Hyperlipoproteinemia(a): clinical significance and treatment options.
Berthold HK; Gouni-Berthold I
Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a)-antisense therapy.
Vogt A
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):51-56. PubMed ID: 30859384
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
7. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
8. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
Tada H; Takamura M; Kawashiri MA
J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
11. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
[TBL] [Abstract][Full Text] [Related]
12. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
[TBL] [Abstract][Full Text] [Related]
14. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
15. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
Vasquez N; Joshi PH
Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
[TBL] [Abstract][Full Text] [Related]
16. Latest developments in the treatment of lipoprotein (a).
Bos S; Yayha R; van Lennep JE
Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
19. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.
Stein EA; Raal F
Cardiovasc Drugs Ther; 2016 Feb; 30(1):101-8. PubMed ID: 26861250
[TBL] [Abstract][Full Text] [Related]
20. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
Boffa MB
Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]